JP2005507000A5 - - Google Patents

Download PDF

Info

Publication number
JP2005507000A5
JP2005507000A5 JP2003537608A JP2003537608A JP2005507000A5 JP 2005507000 A5 JP2005507000 A5 JP 2005507000A5 JP 2003537608 A JP2003537608 A JP 2003537608A JP 2003537608 A JP2003537608 A JP 2003537608A JP 2005507000 A5 JP2005507000 A5 JP 2005507000A5
Authority
JP
Japan
Prior art keywords
dosage form
active agent
period
vitro
released
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003537608A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005507000A (ja
Filing date
Publication date
Priority claimed from US10/024,932 external-priority patent/US20030104052A1/en
Application filed filed Critical
Priority claimed from PCT/US2002/034297 external-priority patent/WO2003035041A1/en
Publication of JP2005507000A publication Critical patent/JP2005507000A/ja
Publication of JP2005507000A5 publication Critical patent/JP2005507000A5/ja
Pending legal-status Critical Current

Links

JP2003537608A 2001-10-25 2002-10-25 下部胃腸管において制限された薬物放出性を有する胃保持性経口投薬形態 Pending JP2005507000A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4581601A 2001-10-25 2001-10-25
US10/024,932 US20030104052A1 (en) 2001-10-25 2001-12-18 Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
PCT/US2002/034297 WO2003035041A1 (en) 2001-10-25 2002-10-25 Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract

Publications (2)

Publication Number Publication Date
JP2005507000A JP2005507000A (ja) 2005-03-10
JP2005507000A5 true JP2005507000A5 (enExample) 2006-01-05

Family

ID=26699053

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003537608A Pending JP2005507000A (ja) 2001-10-25 2002-10-25 下部胃腸管において制限された薬物放出性を有する胃保持性経口投薬形態

Country Status (5)

Country Link
US (3) US7976870B2 (enExample)
EP (1) EP1439826A1 (enExample)
JP (1) JP2005507000A (enExample)
CA (1) CA2409552A1 (enExample)
WO (1) WO2003035041A1 (enExample)

Families Citing this family (202)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110092677A1 (en) * 2001-08-30 2011-04-21 Biorexis Technology, Inc. Modified transferin-antibody fusion proteins
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
US20030152622A1 (en) * 2001-10-25 2003-08-14 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral diuretic
US20030091630A1 (en) * 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
US7612112B2 (en) 2001-10-25 2009-11-03 Depomed, Inc. Methods of treatment using a gastric retained gabapentin dosage
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
BRPI0406749A (pt) 2003-01-13 2005-12-20 Dynogen Pharmaceuticals Inc Métodos relacionados ao tratamento de distúrbios fincionais do intestino e composição farmacêutica
CA2673334C (en) 2003-06-16 2013-11-12 Andrx Pharmaceuticals, Llc Oral extended-release composition
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
US8075872B2 (en) 2003-08-06 2011-12-13 Gruenenthal Gmbh Abuse-proofed dosage form
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE102004032051A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
JP2005132803A (ja) * 2003-10-31 2005-05-26 Ono Pharmaceut Co Ltd 胃内滞留固形剤
US7201920B2 (en) 2003-11-26 2007-04-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of opioid containing dosage forms
EP1691790A1 (en) * 2003-12-12 2006-08-23 Penwest Pharmaceuticals Company Sustained release torsemide dosage forms
AU2004308419B2 (en) * 2003-12-24 2011-06-02 Victory Pharma, Inc. Enhanced absorption of modified release dosage forms
WO2005094789A1 (ja) * 2004-03-31 2005-10-13 Aspion Co., Ltd. S/o型製剤およびその製造方法
US20050239845A1 (en) * 2004-04-16 2005-10-27 Santarus, Inc. Combination of proton pump inhibitor, buffering agent, and prokinetic agent
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
US20080153779A1 (en) 2005-02-01 2008-06-26 Jun Liao Gastric Retention and Controlled Release Delivery System
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
EP1690540A1 (en) * 2005-02-15 2006-08-16 Neuro3D Composition comprising ocaperidone
US20090214640A1 (en) * 2005-03-04 2009-08-27 Intelgenx Cporp. Delayed release pharmaceutical oral dosage form and method of making same
US8722650B1 (en) 2005-06-24 2014-05-13 Medicis Pharmaceutical Corporation Extended-release minocycline dosage forms
US20080242642A1 (en) 2007-04-02 2008-10-02 Medicis Pharmaceutical Corporation Minocycline oral dosage forms for the treatment of acne
US7919483B2 (en) * 2005-06-24 2011-04-05 Medicis Pharmaceutical Corporation Method for the treatment of acne
US9192615B2 (en) 2008-08-06 2015-11-24 Medicis Pharmaceutical Corporation Method for the treatment of acne and certain dosage forms thereof
US8252776B2 (en) * 2007-04-02 2012-08-28 Medicis Pharmaceutical Corporation Minocycline oral dosage forms for the treatment of acne
WO2007074406A2 (en) 2005-07-11 2007-07-05 Pharmena North America Inc. Formulations for treatment of lipoprotein abnormalities comprising a statin a statin and a methylnicotinamide derivative
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US20090176882A1 (en) * 2008-12-09 2009-07-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
PE20080907A1 (es) * 2006-08-31 2008-08-22 Novartis Ag Sistema de suministro de farmaco oral gastro-retentivo de liberacion extendida para valsartan
PE20080669A1 (es) * 2006-09-08 2008-07-18 Drugtech Corp Composicion de liberacion sostenida que comprende levodopa
US8445018B2 (en) 2006-09-15 2013-05-21 Cima Labs Inc. Abuse resistant drug formulation
DE102007011485A1 (de) 2007-03-07 2008-09-11 Grünenthal GmbH Darreichungsform mit erschwertem Missbrauch
GB0707127D0 (en) * 2007-04-13 2007-05-23 Zysis Ltd Pharmaceutical compositions
MX2009013293A (es) 2007-06-04 2010-02-15 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos.
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
TW200914006A (en) * 2007-07-12 2009-04-01 Takeda Pharmaceutical Coated preparation
EP2192892A2 (en) * 2007-07-27 2010-06-09 Depomed, Inc. Pulsatile gastric retentive dosage forms
US9050368B2 (en) 2007-11-13 2015-06-09 Meritage Pharma, Inc. Corticosteroid compositions
HUE038452T2 (hu) 2007-11-13 2018-10-29 Meritage Pharma Inc Gyomor és bélrendszeri gyulladások kezelésére szolgáló kompozíciók
CA2713128C (en) 2008-01-25 2016-04-05 Gruenenthal Gmbh Pharmaceutical dosage form
US8372432B2 (en) 2008-03-11 2013-02-12 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
BRPI0912014A2 (pt) 2008-05-09 2019-03-06 Grünenthal GmbH processo para a preparação de uma formulação em pó intermediária e uma forma de dosagem sólida final sob uso de uma etapa de congelamento por atomização
EP2810951B1 (en) 2008-06-04 2017-03-15 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
CA2730603C (en) 2008-07-16 2019-09-24 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
KR101687781B1 (ko) 2008-08-15 2016-12-20 데포메드 인코퍼레이티드 Cns 장애의 치료 및 예방을 위한 위 체류성 약학적 조성물
WO2010041279A2 (en) 2008-10-08 2010-04-15 V.B. Medicare Pvt. Ltd. Sustained release drug delivery system
US8815971B2 (en) 2008-12-22 2014-08-26 ATRP Solutions, Inc. Control over controlled radical polymerization processes
US8822610B2 (en) 2008-12-22 2014-09-02 ATRP Solutions, Inc. Control over controlled radical polymerization processes
EP2210585A1 (en) 2009-01-16 2010-07-28 Exelgyn SPRM pharmaceutical compositions methods of treatment using them
WO2014036498A2 (en) 2012-08-30 2014-03-06 ATRP Solutions, Inc. Dual mechanism thickening agents for hydraulic fracturing fluids
US8173750B2 (en) 2009-04-23 2012-05-08 ATRP Solutions, Inc. Star macromolecules for personal and home care
US9783628B2 (en) 2009-04-23 2017-10-10 ATRP Solutions, Inc. Dual-mechanism thickening agents for hydraulic fracturing fluids
WO2010123574A1 (en) 2009-04-23 2010-10-28 Atrp Solutions Inc Star macromolecules for personal and home care
JP2012526133A (ja) 2009-05-05 2012-10-25 ベイポジェニックス インコーポレイテッド 炎症を低減させるための新規揮発性麻酔薬製剤およびその使用法
CN102573805A (zh) 2009-07-22 2012-07-11 格吕伦塔尔有限公司 热熔挤出的控制释放剂型
RU2015138422A (ru) 2009-07-22 2018-12-25 Грюненталь Гмбх Стабильная при окислении, прочная на излом лекарственная форма
EP2724739B1 (en) 2009-07-30 2015-07-01 Tandem Diabetes Care, Inc. Portable infusion pump system
FR2949061B1 (fr) * 2009-08-12 2013-04-19 Debregeas Et Associes Pharma Microgranules flottants
WO2011027346A1 (en) * 2009-09-03 2011-03-10 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. A gastroretentive dosage form for oral treatment of domestic animals
WO2011041414A1 (en) 2009-09-30 2011-04-07 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse
US8597681B2 (en) 2009-12-22 2013-12-03 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
US9198861B2 (en) 2009-12-22 2015-12-01 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
US20110150989A1 (en) * 2009-12-22 2011-06-23 Mallinkckrodt Inc. Methods of Producing Stabilized Solid Dosage Pharmaceutical Compositions Containing Morphinans
US9579285B2 (en) 2010-02-03 2017-02-28 Gruenenthal Gmbh Preparation of a powdery pharmaceutical composition by means of an extruder
CN103347517B (zh) 2010-08-11 2018-10-02 德雷克塞尔大学 治疗帕金森病中运动障碍的d3多巴胺受体激动剂
NZ607392A (en) 2010-09-02 2015-03-27 Gruenenthal Chemie Tamper resistant dosage form comprising inorganic salt
BR112013005234A2 (pt) 2010-09-02 2016-05-03 Gruenenthal Gmbh forma de dosagem resistente à violação compreendendo um polímero aniônico.
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
US8435993B2 (en) 2010-12-07 2013-05-07 Philadelphia Health And Education Corporation Methods of inhibiting metastasis from cancer
US9587064B2 (en) 2010-12-08 2017-03-07 ATRP Solutions, Inc. Salt-tolerant star macromolecules
US8476221B2 (en) 2011-03-18 2013-07-02 Halimed Pharmaceuticals, Inc. Methods and compositions for the treatment of metabolic disorders
US8858963B1 (en) 2011-05-17 2014-10-14 Mallinckrodt Llc Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia
US8658631B1 (en) 2011-05-17 2014-02-25 Mallinckrodt Llc Combination composition comprising oxycodone and acetaminophen for rapid onset and extended duration of analgesia
US8741885B1 (en) 2011-05-17 2014-06-03 Mallinckrodt Llc Gastric retentive extended release pharmaceutical compositions
US9561241B1 (en) 2011-06-28 2017-02-07 Medicis Pharmaceutical Corporation Gastroretentive dosage forms for minocycline
US9119793B1 (en) 2011-06-28 2015-09-01 Medicis Pharmaceutical Corporation Gastroretentive dosage forms for doxycycline
PE20141638A1 (es) 2011-07-29 2014-11-22 Gruenenthal Chemie Tableta a prueba de manipulacion que proporciona liberacion de farmaco inmediato
RS56527B1 (sr) 2011-07-29 2018-02-28 Gruenenthal Gmbh Tableta za trenutno oslobađanje leka rezistentna na zloupotrebu
US20130143867A1 (en) 2011-12-02 2013-06-06 Sychroneuron Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
KR101939710B1 (ko) 2011-12-21 2019-01-17 노비라 테라퓨틱스, 인코포레이티드 B형 간염의 항바이러스성 제제
MX356421B (es) 2012-02-28 2018-05-29 Gruenenthal Gmbh Forma de dosificacion resistente a la manipulacion indebida que comprende un compuesto farmacologicamente activo y un polimero anionico.
CN102579344B (zh) * 2012-03-02 2014-02-26 海南美兰史克制药有限公司 氯沙坦钾脂质体固体制剂
DK2838512T3 (en) 2012-04-18 2018-11-19 Gruenenthal Gmbh MANIPULATED AND DOSAGE DUMPED PHARMACEUTICAL DOSAGE FORM
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
US9180242B2 (en) 2012-05-17 2015-11-10 Tandem Diabetes Care, Inc. Methods and devices for multiple fluid transfer
WO2014011830A1 (en) 2012-07-12 2014-01-16 Mallinckrodt Llc Extended release, abuse deterrent pharmaceutical compositions
US9388126B2 (en) 2012-07-19 2016-07-12 Drexel University Sigma receptor ligands and methods of modulating cellular protein homeostasis using same
CN104768544B (zh) 2012-08-09 2017-06-16 迪纳米斯治疗公司 包括葡甲胺或其盐的组合物在制备减少或预防甘油三酯水平增加的药物中的应用
US9550780B2 (en) 2012-09-18 2017-01-24 Auspex Pharmaceuticals, Inc. Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
CA2883641C (en) 2012-09-18 2021-09-14 Auspex Pharmaceuticals, Inc. Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
WO2014085599A1 (en) 2012-11-30 2014-06-05 Acura Pharmaceuticals, Inc. Self-regulated release of active pharmaceutical ingredient
EP2934482A4 (en) * 2012-12-21 2016-07-20 Merck Sharp & Dohme ADMINISTRATIVE FORMULATIONS
AU2014203896B2 (en) 2013-01-07 2018-05-31 The Trustees Of The University Of Pennsylvania Compositions and methods for treating cutaneous T cell lymphoma
MX374990B (es) 2013-02-04 2025-03-06 Pilot Polymer Tech Inc Métodos para la elaboración de macromoléculas en forma de estrella tolerantes a las sales que comprende una pluralidad de brazos poliméricos.
EP3718557A3 (en) 2013-02-25 2020-10-21 Bausch Health Ireland Limited Guanylate cyclase receptor agonist sp-333 for use in colonic cleansing
US10201656B2 (en) 2013-03-13 2019-02-12 Tandem Diabetes Care, Inc. Simplified insulin pump for type II diabetics
US9173998B2 (en) 2013-03-14 2015-11-03 Tandem Diabetes Care, Inc. System and method for detecting occlusions in an infusion pump
US9492608B2 (en) 2013-03-15 2016-11-15 Tandem Diabetes Care, Inc. Method and device utilizing insulin delivery protocols
JP2016514671A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼのアゴニストおよびその使用
JP2016514670A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド 他の薬物と組み合わせたグアニル酸シクラーゼ受容体アゴニスト
US10842802B2 (en) 2013-03-15 2020-11-24 Medicis Pharmaceutical Corporation Controlled release pharmaceutical dosage forms
AR096439A1 (es) 2013-05-29 2015-12-30 Gruenenthal Gmbh Forma de dosificación resistente al uso indebido que contiene una o más partículas
JP6445537B2 (ja) 2013-05-29 2018-12-26 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 1個または複数の粒子を含有する改変防止(tamper−resistant)剤形
JP2016520653A (ja) 2013-06-05 2016-07-14 シンクロニューロン インコーポレイテッド アカンプロサート製剤、それを用いる方法、およびそれを含む合剤
CA2917149C (en) 2013-07-02 2021-02-02 Cineole Corp., Llc Antimicrobial formulation comprising isoamyl hexanoates together with propanoic acid and/or isobutyric acid
GB201311891D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compound
GB201311888D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compounds
US10624862B2 (en) 2013-07-12 2020-04-21 Grünenthal GmbH Tamper-resistant dosage form containing ethylene-vinyl acetate polymer
WO2015054649A2 (en) 2013-10-10 2015-04-16 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of opioid induced dysfunctions
AU2014356581C1 (en) 2013-11-26 2020-05-28 Grunenthal Gmbh Preparation of a powdery pharmaceutical composition by means of cryo-milling
ES2806027T3 (es) 2013-11-26 2021-02-16 Univ Yale Nuevas composiciones penetrantes de células y métodos de uso de las mismas
CN105873589B (zh) 2013-12-03 2019-11-01 奥斯拜客斯制药有限公司 制造苯并喹啉化合物的方法
WO2015089049A1 (en) 2013-12-09 2015-06-18 Thomas Jefferson University Novel methods of treating a neurodegenerative disease in a mammal in need thereof
EP3128996B1 (en) 2014-04-07 2021-06-02 University of Rochester Novel 7-dehydrocholesterol derivatives and methods using same
US20180228907A1 (en) 2014-04-14 2018-08-16 Arvinas, Inc. Cereblon ligands and bifunctional compounds comprising the same
MX2016014738A (es) 2014-05-12 2017-03-06 Gruenenthal Gmbh Formulacion en capsula de liberacion inmediata resistente a alteraciones que comprende tapentadol.
MX2016015417A (es) 2014-05-26 2017-02-22 Gruenenthal Gmbh Multiparticulas protegidas contra vertido de dosis etanolico.
CA2949372C (en) 2014-06-02 2023-08-22 Teva Pharmaceutical Industries Ltd. Expandable gastroretentive dosage form
RU2766335C2 (ru) 2014-06-11 2022-03-15 Массачусетс Инститьют Оф Текнолоджи Удерживаемые структуры и связанные способы
MX385886B (es) 2014-07-03 2025-03-18 Pilot Polymer Tech Inc Macromoleculas estrellas compatibles con tensoactivos.
ES2971639T3 (es) 2014-08-20 2024-06-06 Univ Yale Composiciones y métodos novedosos útiles para tratar o prevenir enfermedades o trastornos hepáticos y favorecer la pérdida de peso
CN114767672A (zh) 2015-03-06 2022-07-22 奥斯拜客斯制药有限公司 氘代丁苯那嗪或包含氘代丁苯那嗪的组合物
JP2018517676A (ja) 2015-04-24 2018-07-05 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 即時放出および溶媒抽出に対する耐性を有する改変防止製剤
WO2016182968A1 (en) 2015-05-08 2016-11-17 Brown University Novel syringolin analogues and methods of making and using same
ES2983910T3 (es) 2015-05-19 2024-10-28 Univ Yale Composiciones para tratar afecciones patológicas de calcificación y métodos que usan las mismas
EP4512394A3 (en) 2015-06-03 2025-10-22 Triastek, Inc. Dosage forms and use thereof
US10829440B2 (en) 2015-06-12 2020-11-10 Brown University Antibacterial compounds and methods of making and using same
NO346258B1 (en) 2015-06-30 2022-05-16 Neurad Ltd Novel breathing control modulating compounds, and methods of making and using same
EP3331499A4 (en) 2015-08-06 2019-04-10 The Johns Hopkins University COMPOSITION AND METHOD FOR THE TREATMENT OF METABOLISM DISEASES
US11103581B2 (en) 2015-08-31 2021-08-31 Acura Pharmaceuticals, Inc. Methods and compositions for self-regulated release of active pharmaceutical ingredient
AU2016319203A1 (en) 2015-09-10 2018-02-22 Grünenthal GmbH Protecting oral overdose with abuse deterrent immediate release formulations
EP3368505B1 (en) 2015-10-28 2023-02-22 Yale University Quinoline amides and methods of using same
US20180371434A1 (en) 2015-11-20 2018-12-27 Yale University Compositions for Treating Ectopic Calcification Disorders, and Methods Using Same
JP2019506383A (ja) 2016-01-11 2019-03-07 シナジー ファーマシューティカルズ インコーポレイテッド 潰瘍性大腸炎を治療するための製剤および方法
WO2017190001A1 (en) 2016-04-29 2017-11-02 The Regents Of The University Of Colorado, A Body Corporate Compounds and compositions useful for treating metabolic syndrome, and methods using same
WO2018026764A1 (en) 2016-08-01 2018-02-08 University Of Rochester Nanoparticles for controlled release of anti-biofilm agents and methods of use
BR112019002355A2 (pt) 2016-08-05 2019-07-16 Yale University composições e métodos para prevenção de acidente vascular cerebral em pacientes pediátricos com anemia falciforme
US10683283B2 (en) 2016-09-01 2020-06-16 Mebias Discovery, Inc. Substituted ureas and methods of making and using same
CN116751200A (zh) 2016-11-07 2023-09-15 爱彼特生物制药公司 含有取代的吡啶酮的三环化合物以及使用其的方法
EP3547974B1 (en) 2016-12-02 2023-11-15 Clexio Biosciences Ltd. Gastric residence system
WO2018136766A1 (en) 2017-01-19 2018-07-26 Temple University-Of The Commonwealth System Of Higher Education Novel bridged bicycloalkyl-substituted aminothizoles and their methods of use
US11098010B2 (en) 2017-03-21 2021-08-24 Arbutus Biopharma Corporation Substituted dihydroindene-4-carboxamides and analogs thereof, and methods using same
JP7108018B2 (ja) 2017-04-17 2022-07-27 イエール ユニバーシティ 急性肺傷害を処置または予防する化合物、組成物および方法
DK3648747T3 (da) 2017-06-16 2022-11-28 Amneal Complex Products Res Llc Gastroretentive doseringsformer til vedvarende frigivelse af lægemidler
US10588863B2 (en) 2017-06-16 2020-03-17 Kashiv Biosciences, Llc Extended release compositions comprising pyridostigmine
US10987311B2 (en) 2017-06-16 2021-04-27 Kashiv Specialty Pharmaceuticals, Llc Extended release compositions comprising pyridostigmine
EP3659307A4 (en) 2017-07-28 2021-09-22 Yale University ANTI-CANCER PRODUCTS AND METHOD FOR MANUFACTURING AND USING THEREOF
CN111527103A (zh) 2017-09-08 2020-08-11 科罗拉多大学董事会,法人团体 用于治疗或预防her驱动的抗药性癌症的化合物、组合物和方法
CA3082043A1 (en) * 2017-11-07 2019-05-16 Rani Therapeutics, Llc Clotting factor preparations for delivery into tissue of the intestinal tract using a swallowable drug delivery device
CN111818929A (zh) 2017-11-27 2020-10-23 由卫生与公众服务部部长代表的美利坚合众国 用于治疗和/或预防牙周疾病的化合物、组合物和方法
WO2019111132A1 (en) 2017-12-04 2019-06-13 Clexio Biosciences Ltd. Long acting gastric residence system
WO2019126216A1 (en) 2017-12-18 2019-06-27 Tris Phama, Inc. Pharmaceutical compositions comprising a floating interpenetrating polymer network forming system
WO2019126218A1 (en) 2017-12-18 2019-06-27 Tris Pharma, Inc. Modified release drug powder composition comprising gastro-retentive raft forming systems having trigger pulse drug release
US11337920B2 (en) 2017-12-18 2022-05-24 Tris Pharma, Inc. Pharmaceutical composition comprising GHB gastro-retentive raft forming systems having trigger pulse drug release
EP3737353A1 (en) 2017-12-18 2020-11-18 Tris Pharma, Inc. Ghb pharmaceutical compositions comprising a floating interpenetrating polymer network forming system
WO2019125184A1 (en) 2017-12-19 2019-06-27 Auckland Uniservices Limited Use of biomarker in cancer therapy
KR102810926B1 (ko) 2017-12-20 2025-05-22 퍼듀 퍼머 엘피 남용 억제 황산모르핀 제형
EP3743060A4 (en) 2018-01-24 2021-11-03 The Rockefeller University ANTIBACTERIAL COMPOUNDS, RELATED COMPOSITIONS AND THEIR METHODS OF USE
MY209656A (en) 2018-01-29 2025-07-29 Univ Duke Compositions and methods of enhancing 5-hydroxytryptophan bioavailability
CA3101680A1 (en) 2018-05-25 2019-11-28 Temple University-Of The Commonwealth System Of Higher Education Eradication of bacterial biofilm using anti-amyloid monoclonal antibodies
KR20210015892A (ko) 2018-05-29 2021-02-10 세르시 테라퓨틱스 인코포레이티드 통증 치료를 위한 화합물, 이를 포함하는 조성물 및 이를 사용하는 방법
WO2019246145A1 (en) 2018-06-18 2019-12-26 Kashiv Biosciences, Llc Extended release compositions comprising pyridostigmine
TWI826492B (zh) 2018-07-27 2023-12-21 加拿大商愛彼特生物製藥公司 經取代四氫環戊[c]吡咯、經取代二氫吡咯,其類似物及使用其之方法
IL280868B1 (en) 2018-08-17 2026-05-01 The Trustees Of The Univ Of Pennsylvania Compositions and methods for treating acute lung injury
CN112839661A (zh) 2018-10-11 2021-05-25 萨尼菲特治疗有限公司 用于治疗异位钙化的肌醇磷酸酯类
WO2020081762A1 (en) 2018-10-19 2020-04-23 Temple University-Of The Commonwealth System Of Higher Education Tamper-resistant drug dosage forms and methods of making and use thereof
TW202415643A (zh) 2018-12-12 2024-04-16 加拿大商愛彼特生物製藥公司 經取代之芳基甲基脲類及雜芳基甲基脲類、其類似物及其使用方法
BR112021014897A2 (pt) 2019-01-30 2021-09-28 Sanifit Therapeutics, S.A. Composto ou um sal farmaceuticamente aceitável do mesmo, e, composição farmacêutica
WO2020159565A1 (en) 2019-02-01 2020-08-06 Cersci Therapeutics, Inc. Methods of treating post-surgical pain with a thiazoline anti-hyperalgesic agent
WO2020159588A1 (en) 2019-02-01 2020-08-06 Cersci Therapeutics, Inc. Methods of treating diabetic neuropathy with a thiazoline anti-hyperalgesic agent
WO2020210697A1 (en) 2019-04-12 2020-10-15 Sdg, Inc. Lipid-based nanoparticles and use of same in optimized insulin dosing regimens
US11684652B2 (en) 2019-05-09 2023-06-27 The Feinstein Institutes For Medical Research HMGB1 antagonist treatment of acute lung injury
WO2020252407A1 (en) 2019-06-12 2020-12-17 The Wistar Institute Acetyl-coa synthetase 2 (acss2) inhibitors and methods using same
US11555010B2 (en) 2019-07-25 2023-01-17 Brown University Diamide antimicrobial agents
EP3818983A1 (en) 2019-11-11 2021-05-12 Sanifit Therapeutics S.A. Inositol phosphate compounds for use in treating, inhibiting the progression, or preventing cardiovascular calcification
WO2021127456A1 (en) 2019-12-19 2021-06-24 Rain Therapeutics Inc. Methods of inhibiting epidermal growth factor receptor proteins
CN116157145A (zh) 2020-06-09 2023-05-23 依诺兹梅制药公司 可溶性enpp1或enpp3蛋白及其用途
CN116546984A (zh) 2020-09-28 2023-08-04 耶鲁大学 5-ht2a受体的选择性激动剂及其使用方法
JP7858645B2 (ja) * 2020-10-30 2026-05-14 トリアステック インコーポレイテッド 胃保持のための薬物剤形
EP4015494A1 (en) 2020-12-15 2022-06-22 Sanifit Therapeutics S.A. Processes for the preparation of soluble salts of inositol phosphates
EP4036097A1 (en) 2021-01-29 2022-08-03 Sanifit Therapeutics S.A. Ip4-4,6 substituted derivative compounds
JP2024528125A (ja) 2021-07-30 2024-07-26 エヴェクシア セラピューティクス, インク. 5-ヒドロキシトリプトファン胃内滞留性剤形
US12409163B2 (en) 2021-07-30 2025-09-09 Evecxia Therapeutics, Inc. Method of enhancing 5-hydroxytryptophan (5-HTP) exposure
US11779567B2 (en) 2021-10-14 2023-10-10 Evecxia Therapeutics, Inc. Method for optimizing 5-hydroxytryptamine function in the brain for therapeutic purposes
KR20250047769A (ko) 2022-07-29 2025-04-04 사니핏 테라퓨틱스 에스.에이. 이소성 석회화의 치료, 진행의 저해, 및 예방에 사용하기 위한 ip4-4,6 치환된 유도체 화합물
TW202412815A (zh) 2022-07-29 2024-04-01 西班牙商薩尼菲特治療公司 Ip5經取代化合物
CN115184371B (zh) * 2022-08-05 2023-04-25 深圳市俱进纸品包装有限公司 一种礼盒印刷的瑕疵视觉检测装置
IL319372A (en) 2022-09-06 2025-05-01 Hadasit Med Res Service Combinations involving psychedelic drugs for the treatment of chronic schizophrenia and other neuropsychiatric and neurological disorders
KR102910352B1 (ko) * 2023-01-02 2026-01-09 일양약품주식회사 베타네콜을 함유하는 안정한 방출 제어형 약제학적 조성물 및 이의 제조방법
JP2026513019A (ja) 2023-02-03 2026-04-22 トリス・フアルマ・インコーポレーテツド 1晩1回の低ナトリウムオキシベート組成物
KR20260053367A (ko) 2023-08-14 2026-04-21 뉴림 파머슈티칼스(1991) 리미티드 Gal475 조성물 및 그의 사용 방법
WO2025162971A1 (en) 2024-01-31 2025-08-07 Sanifit Therapeutics, S.A. Substituted ip5 compounds for use in the treatment, inhibition of progression, and prevention of ectopic calcification
WO2025217094A1 (en) 2024-04-08 2025-10-16 University Of Rochester Interleukin receptor-associated kinase (irak) protac degraders and medical use thereof
WO2025217096A1 (en) 2024-04-08 2025-10-16 University Of Rochester Inhibitors of leucine-rich repeat kinase 2 (lrrk2) and medical uses thereof
WO2025217379A1 (en) 2024-04-10 2025-10-16 University Of Rochester Drug treatment for macular degeneration
WO2026050206A1 (en) 2024-08-27 2026-03-05 Ironwood Pharmaceuticals, Inc. Combinations of glp-1 and guanylate cyclase c (gc-c) receptor agonists

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA722664B (en) 1971-05-18 1973-01-31 Smith Kline French Lab Lyered bolus for animal husbandry providing for immediate and sustained release of medicament
US4670444B1 (en) 1980-09-03 1999-02-09 Bayer Ag and-naphthyridine-3-carboxylic acids and antibacte7-amino-1-cyclopropyl-4-oxo-1,4-dihydro-quinoline-rial agents containing these compounds
US4434153A (en) 1982-03-22 1984-02-28 Alza Corporation Drug delivery system comprising a reservoir containing a plurality of tiny pills
HU187215B (en) 1983-01-26 1985-11-28 Egyt Gyogyszervegyeszeti Gyar Method for producing pharmaceutical product of high actor content and prolonged effect
US4690824A (en) 1983-07-07 1987-09-01 Redi-Rowell, Inc. Solid pharmaceutical formulations for slow, zero order release via controlled surface erosion: expanded range
JPS6124516A (ja) 1984-07-12 1986-02-03 Fujisawa Pharmaceut Co Ltd 持続性錠剤
US4753801A (en) 1985-10-25 1988-06-28 Eli Lilly And Company Sustained release tablets
IL77186A0 (en) 1985-11-29 1986-04-29 Touitou Elka Pharmaceutical insulin composition
IT1188212B (it) 1985-12-20 1988-01-07 Paolo Colombo Sistema per il rilascio a velocita' controllata di sostanze attive
IT1201136B (it) 1987-01-13 1989-01-27 Resa Farma Compressa per uso farmaceutico atta al rilascio in tempi successivi di sostanze attive
US4851232A (en) 1987-02-13 1989-07-25 Alza Corporation Drug delivery system with means for obtaining desirable in vivo release rate pattern
US4786503A (en) 1987-04-06 1988-11-22 Alza Corporation Dosage form comprising parallel lamine
US5002772A (en) 1988-05-31 1991-03-26 Pfizer Inc. Gastric retention system for controlled drug release
US5007790A (en) * 1989-04-11 1991-04-16 Depomed Systems, Inc. Sustained-release oral drug dosage form
US5085865A (en) 1989-04-12 1992-02-04 Warner-Lambert Company Sustained release pharmaceutical preparations containing an analgesic and a decongestant
DK469989D0 (da) 1989-09-22 1989-09-22 Bukh Meditec Farmaceutisk praeparat
US5064656A (en) 1989-11-14 1991-11-12 Dr. Gergely & Co. Uncoated pharmaceutical reaction tablet
IT1237904B (it) 1989-12-14 1993-06-18 Ubaldo Conte Compresse a rilascio a velocita' controllata delle sostanze attive
US5232704A (en) 1990-12-19 1993-08-03 G. D. Searle & Co. Sustained release, bilayer buoyant dosage form
DE69222006T2 (de) 1991-10-30 1998-01-22 Glaxo Group Ltd Mehrschichtzusammensetzungen enthaltend Histamin- oder Serotonin- Antagonisten
DE4209160A1 (de) 1992-03-20 1993-09-30 Bauer Kurt Heinz Prof Dr Vernetzte Polysaccharide, Verfahren zu ihrer Herstellung und ihre Verwendung
US5582837A (en) 1992-03-25 1996-12-10 Depomed, Inc. Alkyl-substituted cellulose-based sustained-release oral drug dosage forms
US5260068A (en) 1992-05-04 1993-11-09 Anda Sr Pharmaceuticals Inc. Multiparticulate pulsatile drug delivery system
IT1255522B (it) 1992-09-24 1995-11-09 Ubaldo Conte Compressa per impiego terapeutico atta a cedere una o piu' sostanze attive con differenti velocita'
IT1256393B (it) 1992-11-17 1995-12-04 Inverni Della Beffa Spa Forme matriciali multistrato per il rilascio controllato di principi attivi
US5260069A (en) 1992-11-27 1993-11-09 Anda Sr Pharmaceuticals Inc. Pulsatile particles drug delivery system
US5358502A (en) 1993-02-25 1994-10-25 Pfizer Inc PH-triggered osmotic bursting delivery devices
US5382435A (en) 1993-03-24 1995-01-17 Southwest Research Institute Microparticulate pharmaceutical delivery system
IT1264517B1 (it) 1993-05-31 1996-09-24 Ekita Investments Nv Compressa farmaceutica atta al rilascio in tempi successivi dei principi attivi in essa veicolati
IT1264696B1 (it) 1993-07-09 1996-10-04 Applied Pharma Res Forme farmaceutiche destinate alla somministrazione orale in grado di rilasciare sostanze attive a velocita' controllata e differenziata
IT1265240B1 (it) 1993-11-30 1996-10-31 Ekita Investments Nv Compressa farmaceutica a rilascio controllato, di forma lenticolare
US5393765A (en) 1993-12-13 1995-02-28 Hoffmann-La Roche Inc. Pharmaceutical compositions with constant erosion volume for zero order controlled release
GB9326267D0 (en) 1993-12-23 1994-02-23 Scherer Corp R P Expulsion of material
DE4406424A1 (de) 1994-02-28 1995-08-31 Bayer Ag Expandierbare Arzneiformen
US5458888A (en) 1994-03-02 1995-10-17 Andrx Pharmaceuticals, Inc. Controlled release tablet formulation
US5458887A (en) 1994-03-02 1995-10-17 Andrx Pharmaceuticals, Inc. Controlled release tablet formulation
US20030056896A1 (en) * 1995-05-12 2003-03-27 Frank Jao Effective therapy for epilepsies
US5464633A (en) 1994-05-24 1995-11-07 Jagotec Ag Pharmaceutical tablets releasing the active substance after a definite period of time
US5945125A (en) 1995-02-28 1999-08-31 Temple University Controlled release tablet
US5695781A (en) * 1995-03-01 1997-12-09 Hallmark Pharmaceuticals, Inc. Sustained release formulation containing three different types of polymers
ATE214596T1 (de) 1995-04-14 2002-04-15 Pharma Pass Feste zusammensetzungen mit einem nicht-amorphem wirkstoff und polyäthylenoxyd
US5736159A (en) 1995-04-28 1998-04-07 Andrx Pharmaceuticals, Inc. Controlled release formulation for water insoluble drugs in which a passageway is formed in situ
US5811126A (en) 1995-10-02 1998-09-22 Euro-Celtique, S.A. Controlled release matrix for pharmaceuticals
JP3220373B2 (ja) 1995-11-28 2001-10-22 バイエル薬品株式会社 持続性ニフエジピン製剤
US5840332A (en) 1996-01-18 1998-11-24 Perio Products Ltd. Gastrointestinal drug delivery system
US5783212A (en) 1996-02-02 1998-07-21 Temple University--of the Commonwealth System of Higher Education Controlled release drug delivery system
IT1282650B1 (it) 1996-02-19 1998-03-31 Jagotec Ag Compressa farmaceutica,caratterizzata da elevato aumento di volume a contatto con liquidi biologici
US6048547A (en) 1996-04-15 2000-04-11 Seth; Pawan Process for manufacturing solid compositions containing polyethylene oxide and an active ingredient
EP0859603B1 (en) 1996-07-08 2008-12-17 Penwest Pharmaceuticals Co. Sustained release matrix for high-dose insoluble drugs
US5972389A (en) * 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
IT1289160B1 (it) 1997-01-08 1998-09-29 Jagotec Ag Compressa farmaceutica completamente rivestita per il rilascio controllato di principi attivi che presentano problemi di
CA2277220A1 (en) 1997-01-10 1998-07-16 Abbott Laboratories Tablet for the controlled release of active agents
US5891474A (en) 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same
US5837379A (en) 1997-01-31 1998-11-17 Andrx Pharmaceuticals, Inc. Once daily pharmaceutical tablet having a unitary core
US5840329A (en) 1997-05-15 1998-11-24 Bioadvances Llc Pulsatile drug delivery system
GB9710699D0 (en) * 1997-05-24 1997-07-16 Danbiosyst Uk Gastro-retentive controlled release system
US6635280B2 (en) 1997-06-06 2003-10-21 Depomed, Inc. Extending the duration of drug release within the stomach during the fed mode
ES2248908T7 (es) 1997-06-06 2014-11-24 Depomed, Inc. Formas de dosificación de fármacos por vía oral y retención gástrica para liberación continuada de fármacos altamente solubles
PT1003476E (pt) 1997-08-11 2005-05-31 Alza Corp Forma de dosagem de agente activo de libertacao prolongada adaptada para retencao gastrica
IT1294760B1 (it) 1997-09-03 1999-04-12 Jagotec Ag Procedimento per la preparazione di compresse farmaceutiche in grado di cedere,secondo schemi predeterminabili, principi attivi poco
IN186245B (enExample) 1997-09-19 2001-07-14 Ranbaxy Lab Ltd
US5916595A (en) 1997-12-12 1999-06-29 Andrx Pharmaceutials, Inc. HMG co-reductase inhibitor
TW357614U (en) 1998-03-12 1999-05-01 Wen-Neng Liu Retractable safety syringe needle for hypodermic injection
FR2781152B1 (fr) * 1998-07-20 2001-07-06 Permatec Tech Ag Utilisation d'un polymere de type acrylique en tant qu'agent de desagregation
FR2784583B1 (fr) 1998-10-16 2002-01-25 Synthelabo Composition pharmaceutique a residence gastrique et a liberation controlee
AU2199500A (en) * 1998-12-23 2000-07-31 Alza Corporation Gastric retention dosage form having multiple layers
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6562375B1 (en) 1999-08-04 2003-05-13 Yamanouchi Pharmaceuticals, Co., Ltd. Stable pharmaceutical composition for oral use
NZ518739A (en) 1999-11-02 2004-12-24 Depomed Inc Pharmacological inducement of the fed mode for enhanced drug administration to the stomach
PT1251832E (pt) 2000-02-04 2007-01-31 Depomed Inc Forma de dosagem constituída por invólucro-e-núcleo que conduz a uma libertação do fármaco de ordem zero
US6368628B1 (en) 2000-05-26 2002-04-09 Pharma Pass Llc Sustained release pharmaceutical composition free of food effect
US6488962B1 (en) * 2000-06-20 2002-12-03 Depomed, Inc. Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
US6451808B1 (en) 2000-10-17 2002-09-17 Depomed, Inc. Inhibition of emetic effect of metformin with 5-HT3 receptor antagonists
TWI259836B (en) 2001-04-12 2006-08-11 Astrazeneca Ab Modified release formulation suitable for antiarrhythmic compounds
US20030031711A1 (en) 2001-05-29 2003-02-13 Fara John W. Method of treating gastroesophageal reflux disease and nocturnal acid breakthrough
US20030091630A1 (en) 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
US20030152622A1 (en) 2001-10-25 2003-08-14 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral diuretic
US6682759B2 (en) 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs

Similar Documents

Publication Publication Date Title
JP2005506998A5 (enExample)
ES2270982T3 (es) Forma de dosificacion de nucleo y carcasa que se aproxima a una liberacion del farmaco de orden cero.
Gupta et al. Recent trends in oral drug delivery: a review
US6632451B2 (en) Delayed total release two pulse gastrointestinal drug delivery system
Pinto Site-specific drug delivery systems within the gastro-intestinal tract: from the mouth to the colon
JP2016166239A (ja) 膨潤性の制御放出経口剤形の胃における滞留性を増強するための錠剤の形状
MXPA04003793A (es) Mezclas optimas de polimeros para tabletas retentivas gastricas.
CZ219898A3 (cs) Systém pro podání léku do gastrointestinálního traktu
JP2001519379A (ja) 遅延性総放出胃腸薬物送達システム
JP2010502642A (ja) バルサルタンのための持続放出性胃滞留型経口薬物送達システム
JP2011500552A (ja) 胃腸障害を処置するための医薬用組み合わせおよび組成物
JP2013512250A5 (enExample)
US20240041781A1 (en) Two-stage microparticle-based therapeutic delivery system and method
JP7431886B2 (ja) 新規テビペネムピボキシルの即放性および調節放出性経口剤形
US20110182987A1 (en) Pharmaceutical dosage form for the site-specific delivery of more than one active pharmaceutical ingredient
Zanke et al. Recent advance in gastroretantive drug delivery system (GRDDS)
Subramani et al. A Novel Approach on Role of Polymers Used in Sustained Re-lease Drug Delivery System—A Review
WO2010100657A2 (en) A novel oral controlled release dosage forms for water soluble drugs
JP2004002320A (ja) 生体内で相転移する液状マトリックスおよび液状経口製剤
US9119793B1 (en) Gastroretentive dosage forms for doxycycline
WO2007010847A1 (ja) 徐放製剤
EP1512394B1 (en) Universal controlled-release composition comprising chitosan
US20210154161A1 (en) Modified-release bucillamine compositions, kits, and methods for treating cystinuria, arthritis, gout, and related disorders
US9561241B1 (en) Gastroretentive dosage forms for minocycline
CN105828812A (zh) 胃内滞留口服药物组合物